# Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

> **NCT02179086** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **NRG Oncology** · enrollment: 606 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **RADIATION:** 3-Dimensional Conformal Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **RADIATION:** Intensity-Modulated Radiation Therapy
- **OTHER:** Laboratory Biomarker Analysis
- **RADIATION:** Photon Beam Radiation Therapy
- **RADIATION:** Proton Beam Radiation Therapy
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT02179086
- **Lead sponsor:** NRG Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-12-04
- **Primary completion:** 2025-07-07
- **Final completion:** 2026-12-31
- **Target enrollment:** 606 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02179086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02179086, "Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02179086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*